Phase I Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer

NCT07009457 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Widespread Small Cell Lung Cancer

Interventions

DRUG: SHR-1316 (sc) Injection
DRUG: SHR-1316 Injection
DRUG: Carboplatin Injection
DRUG: Etoposide Injection

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.